

## Prof. AYŞE ERCAN

### Personal Information

Office Phone: [+90 312 305 2075](tel:+903123052075)

Office Phone: [+90 312 305 1499](tel:+903123051499)

Fax Phone: [+90 312 311 4777](tel:+903123114777)

Email: [aysercan@hacettepe.edu.tr](mailto:aysercan@hacettepe.edu.tr)

Web: <https://avesis.hacettepe.edu.tr/aysercan>

Address: Hacettepe Üniversitesi Eczacılık Fakültesi Biyokimya Anabilim Dalı 06100 Sıhhiye Ankara

### International Researcher IDs

ORCID: 0000-0003-1499-2410

ScopusID: 6603694323

Yoksis Researcher ID: 168917

### Education Information

Doctorate, Hacettepe University, Tıp Fakültesi, Biyokimya, Turkey 2001 - 2006

Postgraduate, Middle East Technical University, Fen Fakültesi, Biyokimya, Turkey 1998 - 2001

Undergraduate, Hacettepe University, Fen Fakültesi, Biyokimya, Turkey 1994 - 1998

### Foreign Languages

English, C1 Advanced

French, C1 Advanced

### Research Areas

Basic Pharmaceutics Sciences, Health Sciences, Pharmacology and Therapeutics, Biochemistry, Life Sciences, Biochemistry, Biomolecules, Enzymology, Molecular Biochemistry, Molecular Biology and Genetics, Genetic Disorders, Molecular Biology of Cancer, Natural Sciences

### Academic Titles / Tasks

Professor, Hacettepe University, Eczacılık Fakültesi, Temel Eczacılık Bilimleri Bölümü, 2021 - Continues

Associate Professor, Hacettepe University, Eczacılık Fakültesi, Temel Eczacılık Bilimleri Bölümü, 2013 - 2021

Assistant Professor, Hacettepe University, Eczacılık Fakültesi, Temel Eczacılık Bilimleri Bölümü, 2009 - 2013

Lecturer PhD, Hacettepe University, Eczacılık Fakültesi, Temel Eczacılık Bilimleri Bölümü, 2007 - 2009

Research Assistant, Hacettepe University, Eczacılık Fakültesi, Temel Eczacılık Bilimleri Bölümü, 2006 - 2007

Research Assistant, Hacettepe University, Tıp Fakültesi (İngilizce), Temel Tıp Bilimleri Bölümü, 2001 - 2006

### Academic and Administrative Experience

Hacettepe Üniversitesi, Eczacılık Fakültesi, Temel Eczacılık Bilimleri Bölümü, 2013 - 2017

## Courses

BİYOKİMYA I, Undergraduate, 2016 - 2017

BİYOMOLEKÜLER ARAŞTIRMA VE TANI TEKNİKLERİ, Undergraduate, 2016 - 2017

Kanser Biyokimyası, Undergraduate, 2016 - 2017

## Advising Theses

ERCAN A., ERSU B., ERSU B., TİTANYUM ALAŞIM YÜZEYLERİN SELEKTİF LAZER ERGİTME İŞLEMİ İLE KAPLANMASI SONRASI YÜZEY KARAKTERİZASYONUNUN SAOS-2 HÜCRE PROLİFERASYONU ÜZERİNE ETKİSİNİN İNCELENMESİ, Doctorate, E.ORKUN(Student), 2017

ERCAN A., Doksorubisinin luminal A ve üçlü negatif meme kanseri hücrelerinde P53 apoptoz yolağı ve çoklu ilaç direnci üzerinde farklı etkilerinin incelenmesi, Doctorate, S.ÖNCÜL(Student), 2017

ERCAN A., Karaciğer ve meme kanseri hücreleri ile embriyonik böbrek hücrelerinde doksorubisinin apoptotik genlerin ve MDR-1 geninin ekspresyon düzeylerine etkisi, Postgraduate, S.ÖNCÜL(Student), 2013

ERCAN A., Karaciğer ve meme kanseri hücrelerinde çoklu ilaç direnci ve apoptotik proteinlerin gen ekspresyon düzeylerinin incelenmesi, Postgraduate, G.AYDIN(Student), 2011

## Published journal articles indexed by SCI, SSCI, and AHCI

- I. **4-{3-[(Pyridin-4-ylmethyl)amino]-[1,2,4]triazolo[4,3-b][1,2,4]triazin-6-yl}phenol: An improved anticancer agent in hepatocellular carcinoma and a selective MDR1/MRP modulator**  
Khatir Z. Z., Di Sotto A., Percaccio E., TÜYLÜ KÜÇÜKKILINÇ Z. T., ERCAN A., Chippindale A. M., Valipour M., Irannejad H.  
Archiv der Pharmazie, 2024 (SCI-Expanded)
- II. **Phenelzine protects against acetaminophen induced apoptosis in HepG2 cells**  
TÜYLÜ KÜÇÜKKILINÇ Z. T., ERCAN A.  
Drug and Chemical Toxicology, vol.47, no.1, pp.81-89, 2024 (SCI-Expanded)
- III. **Effects of single or combined exposure to bisphenol A and mono(2-ethylhexyl)phthalate on oxidant/antioxidant status, endoplasmic reticulum stress, and apoptosis in HepG2 cell line**  
ÖZKEMAHLI K. G., ERKEKOĞLU Ü. P., ERCAN A., ZEYBEK N. D., YERSAL N., GÜMÜŞEL B.  
ENVIRONMENTAL SCIENCE AND POLLUTION RESEARCH, vol.30, pp.12189-12206, 2023 (SCI-Expanded)
- IV. **Pharmacometabolomic assessment of vitamin E loaded human serum albumin nanoparticles on HepG2 cancer cell lines**  
Şenol Y., KAPLAN O., VARAN C., Demirtürk N., Öncül S., Fidan B. B., ERCAN A., BİLENSOY E., ÇELEBİER M.  
Journal of Drug Delivery Science and Technology, vol.79, 2023 (SCI-Expanded)
- V. **Plasma irisin and metabolomic response differ between concentric and isometric exercise Effets différents de l'exercice concentrique et de l'exercice isométrique sur l'irisine plasmatique et la réponse métabolomique**  
KARA Ö. S., ERCAN A., ÇELEBİER M., KAPLAN O., ÖNCÜL S., KORKUSUZ F.  
Science and Sports, vol.37, no.7, pp.610-617, 2022 (SCI-Expanded)
- VI. **A different approach to immunochemotherapy for colon Cancer: Development of nanoplexes of cyclodextrins and Interleukin-2 loaded with 5-FU**  
Akkin S., VARAN G., AKSÜT D., Malanga M., ERCAN A., ŞEN M., BİLENSOY E.  
INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol.623, 2022 (SCI-Expanded)
- VII. **Q-tof lc/ms-based untargeted metabolomics approach to evaluate the effect of folate-conjugated cyclodextrins on triple-negative breast cancer cells**  
Varol I., KAPLAN O., Erdoğan N., Öncül S., Nielsen T. T., ERCAN A., BİLENSOY E., ÇELEBİER M.  
Current Pharmaceutical Analysis, vol.17, no.10, pp.1272-1281, 2021 (SCI-Expanded)

- VIII. **An investigation of the effect of surface characterization on Saos-2 cell proliferation after coating of titanium alloy surfaces by a selective laser melting process**  
Olçay E. O., ERCAN A., ÖNCÜL S., Arifagaoglu O., ERSU B.  
Surface and Coatings Technology, vol.422, 2021 (SCI-Expanded)
- IX. **Antitumor activity of Ankaferd Blood Stopper (R) on MCF-7 breast cancer: A proteomic approach to ascertain the mechanism of the action**  
Zeki O. C., NENNİ M., ÇELEBİER M., ÖNCÜL S., ERCAN A., SÜSLÜ İ., Haznedarog I. C.  
JOURNAL OF HERBAL MEDICINE, vol.28, 2021 (SCI-Expanded)
- X. **Polycationic cyclodextrin nanoparticles induce apoptosis and affect antitumoral activity in HepG2 cell line: An evaluation at the molecular level**  
ERCAN A., ÇELEBİER M., ÖNCÜL S., VARAN G., KOÇAK E., Benito J. M., BİLENSOY E.  
International Journal of Pharmaceutics, vol.598, 2021 (SCI-Expanded)
- XI. **Recent Approaches to Integrate Multiomics Data on System Biology**  
ÇELEBİER M., ERCAN A.  
CURRENT ANALYTICAL CHEMISTRY, vol.17, no.9, pp.1243-1251, 2021 (SCI-Expanded)
- XII. **An allomaltol derivative triggers distinct death pathways in luminal a and triple-negative breast cancer subtypes**  
ERCAN A., ÖNCÜL S., Karakaya G., Aytemir M.  
BIOORGANIC CHEMISTRY, vol.105, 2020 (SCI-Expanded)
- XIII. **A kojic acid derivative promotes intrinsic apoptotic pathway of hepatocellular carcinoma cells without incurring drug resistance**  
ÖNCÜL S., Karakaya G., Dilsiz Aytemir M., ERCAN A.  
Chemical Biology and Drug Design, vol.94, no.6, pp.2084-2093, 2019 (SCI-Expanded)
- XIV. **Synthesis, computational molecular docking analysis and effectiveness on tyrosinase inhibition of kojic acid derivatives**  
Karakaya G., TÜRE A., ERCAN A., ÖNCÜL S., Aytemir M.  
Bioorganic Chemistry, vol.88, 2019 (SCI-Expanded)
- XV. **HGF-1 proliferation on titanium dental implants treated with laser melting technology**  
Arifagaoglu O., ÖNCÜL S., ERCAN A., Olçay O., ERSU B.  
NIGERIAN JOURNAL OF CLINICAL PRACTICE, vol.22, no.2, pp.251-257, 2019 (SCI-Expanded)
- XVI. **Synthesis and anticancer activity of benzimidazole/benzoxazole substituted triazolotriazines in hepatocellular carcinoma**  
Dadashpour S., Küçükklınç T. T., ERCAN A., Hosseinimehr S. J., Naderi N., Irannejad H.  
Anti-Cancer Agents in Medicinal Chemistry, vol.19, no.17, pp.2120-2129, 2019 (SCI-Expanded)
- XVII. **Synthesis and Cytotoxic Evaluation of Kojic Acid Derivatives with Inhibitory Activity on Melanogenesis in Human Melanoma Cells**  
KARAKAYA G., ÖNCÜL S., ERCAN A., AYTEMİR M.  
Anti-Cancer Agents In Medicinal Chemistry, vol.18, pp.1-12, 2018 (SCI-Expanded)
- XVIII. **Global omics strategies to investigate the effect of cyclodextrin nanoparticles on MCF-7 breast cancer cells**  
ERCAN A., ÇELEBİER M., VARAN G., ÖNCÜL S., Nenni M., KAPLAN O., BİLENSOY E.  
European Journal of Pharmaceutical Sciences, vol.123, pp.377-386, 2018 (SCI-Expanded)
- XIX. **Breast cancer treatment capacity of an allomaltol derivative from the standpoint of apoptosis and multidrug resistance**  
Oncul S., ERCAN A., Karakaya G., Aytemir M.  
FEBS OPEN BIO, vol.8, pp.298, 2018 (SCI-Expanded)
- XX. **Discrimination of the Effects of Doxorubicin on Two Different Breast Cancer Cell Lines on Account of Multidrug Resistance and Apoptosis**  
ÖNCÜL S., ERCAN A.  
INDIAN JOURNAL OF PHARMACEUTICAL SCIENCES, vol.79, no.4, pp.599-607, 2017 (SCI-Expanded)
- XXI. **Cholesterol-Targeted Anticancer and Apoptotic Effects of Anionic and Polycationic Amphiphilic**

### **Cyclodextrin Nanoparticles**

VARAN G., ÖNCÜL S., ERCAN A., BENITO J. M., MELLET C. O., BİLENSOY E.

Journal of Pharmaceutical Sciences, vol.105, no.10, pp.3172-3182, 2016 (SCI-Expanded)

- XXII. **Evaluation of selective human MAO inhibitory activities of some novel pyrazoline derivatives**  
Salgin-Goksen U., Yabanoglu-Ciftci S., ERCAN A., Yelekci K., UÇAR G., Gokhan-Kelekci N.  
JOURNAL OF NEURAL TRANSMISSION, vol.120, no.6, pp.863-873, 2013 (SCI-Expanded)
- XXIII. **Pyrazoline based MAO inhibitors: Synthesis, biological evaluation and SAR studies**  
JAGRAT M., BEHERA J., YABANOGLU S., ERCAN A., UÇAR G., SINHA B. N., SANKARAN V., BASU A., JAYAPRAKASH V.  
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol.21, no.14, pp.4296-4300, 2011 (SCI-Expanded)
- XXIV. **The determination of matrix metalloproteinase 9 activity and gene expression levels in Behcet's disease patients with aneurysmal complications**  
AKSOY Y., ERCAN A., Dalmizrak O., CANPINAR H., DURMAZLAR S. P. K., BAYAZIT M.  
CLINICAL RHEUMATOLOGY, vol.30, no.4, pp.515-519, 2011 (SCI-Expanded)
- XXV. **Synthesis and molecular modeling of some novel hexahydroindazole derivatives as potent monoamine oxidase inhibitors**  
GOKHAN-KELEKCI N., SIMSEK O. O., ERCAN A., Yelekci K., Sahin Z. S., Isik S., UCAR G., BILGIN A. A.  
BIOORGANIC & MEDICINAL CHEMISTRY, vol.17, no.18, pp.6761-6772, 2009 (SCI-Expanded)
- XXVI. **Mitochondrial Respiratory Chain Enzyme Activities, mtDNA Variants and Gene Expression Levels in Idiopathic Parkinson's Disease**  
ERCAN A., KULAKSIZ G., Dalmizrak O., Muftuoglu M., OGUS H., CAVDAR L., INAN L., Ozer N.  
TURKISH JOURNAL OF BIOCHEMISTRY-TURK BIYOKIMYA DERGISI, vol.34, no.2, pp.97-104, 2009 (SCI-Expanded)
- XXVII. **Pyrazoline-based mycobactin analogues as MAO-inhibitors**  
Jayaprakash V., Sinha B. N., UÇAR G., ERCAN A.  
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol.18, no.24, pp.6362-6368, 2008 (SCI-Expanded)
- XXVIII. **Effects of Three Actinic Keratosis Mutations on Apoptosis**  
ERCAN A., OGUS I. H.  
TURKISH JOURNAL OF BIOCHEMISTRY-TURK BIYOKIMYA DERGISI, vol.33, no.4, pp.197-201, 2008 (SCI-Expanded)
- XXIX. **Mitochondrial complex I and IV activities in leukocytes from patients with parkin mutations**  
MUFTUOGLU M., ELIBOL B., DALMIZRAK O., Ercan A., KULAKSIZ G., OGUS H., DALKARA T., OZER N.  
MOVEMENT DISORDERS, vol.19, no.5, pp.544-548, 2004 (SCI-Expanded)
- XXX. **Simple, high-yield purification of xanthine oxidase from bovine milk**  
OZER N., MUFTUOGLU M., ATAMAN D., Ercan A., OGUS I.  
JOURNAL OF BIOCHEMICAL AND BIOPHYSICAL METHODS, vol.39, no.3, pp.153-159, 1999 (SCI-Expanded)

### **Articles Published in Other Journals**

- I. **Exposure of Hepatocellular Carcinoma Cells to Ankaferd Blood Stopper (R) Alters Cell Death Signaling Networks Confirmed by Oncoproteomic and Genomic Profiling Studies**  
NENİ M., ÖNCÜL S., ERCAN A., ÇELEBİER M., SÜSLÜ İ., HAZNEDAROĞLU İ. C.  
CURRENT TRADITIONAL MEDICINE, vol.7, no.2, pp.223-235, 2021 (ESCI)
- II. **Comparison of cell lysis techniques via q-tof lc/ms**  
KAPLAN O., ÖNCÜL S., ERCAN A., ÇELEBİER M.  
Mass Spectrometry Letters, vol.11, no.2, pp.36-40, 2020 (ESCI)
- III. **Kojic acid derivatives as potential anticancer agents: Synthesis and cytotoxic evaluation on A375 human malignant melanoma cells**  
Karakaya G., ERCAN A., ÖNCÜL S., Aytimir M.  
JOURNAL OF RESEARCH IN PHARMACY, vol.23, no.4, pp.596-607, 2019 (ESCI)

## Refereed Congress / Symposium Publications in Proceedings

- I. **Proteomic Investigation of Ankaferd Hemostat Application on MCF-7 Breast Cancer Cell Line**  
ZEKİ Ö. C., NENNİ M., ÖNCÜL S., ERCAN A., SÜSLÜ İ., HAZNEDAROĞLU İ. C.  
International Multidisciplinary Symposium on Drug Research and Development (DRD), 1 - 03 July 2019
- II. **A Metabolomic Study to Investigate the Effect of Folate Conjugated Nanoparticles on Triple Negative Breast Cancer Cells**  
ERCAN A., ÇELEBİER M., varol ı., KAPLAN O., Varan G., ÖNCÜL S., KOÇAK E., BİLENSOY E.  
EUFEPS Annual Meeting 2019 PERSONALIZED MEDICINES,TARGETED THERAPIES,PRECISION DRUG DELIVERY, 6 - 08 March 2019
- III. **The effect of polycationic amphiphilic cyclodextrin nanoparticles on mda-mb cancer cells: A metabolomic approach to understand the mechanism**  
ÇELEBİER M., KAPLAN O., VARAN G., ÖNCÜL S., KOÇAK E., ERCAN A., BİLENSOY E.  
12 th International symposium on pharmaceutical sciences, 26 June 2018
- IV. **Exploring Cell Death Mechanism In A375 Human Malign Melanoma Cells Upon Treatment A Mannich Base Derivative**  
ERCAN A., AYTEMİR M.  
12th International Symposium on Pharmaceutical Sciences (ISOPS 12th), 26 - 29 June 2018
- V. **Investigation of The Effect of Commercial Herbal Mixture on HepG2 Liver Cancer Cell Line by Proteomic Approach**  
NENNİ M., ÖNCÜL S., ERCAN A., SÜSLÜ İ., ÇELEBİER M., HAZNEDAROĞLU İ. C.  
12th International Symposium on Pharmaceutical Sciences, 26 - 29 June 2018
- VI. **Breast Cancer Treatment Capacity of a Allomaltol Derivative from the Standpoint of Apoptosis and Multidrug Resistance**  
ÖNCÜL S., ERCAN A., KARAKAYA G., AYTEMİR M.  
The 43rd FEBS Congress, Prag, Czech Republic, 07 June 2018, pp.1
- VII. **GENOMIC AND METABOLOMIC STUDIES OF POLYCATIONIC AMPHIPHILIC CYCLODEXTRIN NANOPARTICLES ON HEPG2 CELL LINE**  
ERCAN A., ÇELEBİER M., Varan G., ÖNCÜL S., KOÇAK E., KAPLAN O., BİLENSOY E.  
EUFEPS Annual Meeting 2018 Crossing Barriers for Future Medicines, 24 - 26 May 2018
- VIII. **Synthesis of Some New Mannich Bases with Anti-tyrosinase Activity.**  
AYTEMİR M., KARAKAYA G., ERCAN A., ÖNCÜL S.  
2nd International Gazi Pharma Symposium Series (GPSS), 11 - 13 October 2017
- IX. **An in vitro investigation of human gingival fibroblast proliferation on dental titanium implants treated with selective laser melting technology**  
ARİFAĞAOĞLU Ö., ÖNCÜL S., ERCAN A., ERSU B.  
26th Annual Scientific Meeting of the European Association for Osseointegration, Madrid, Spain, 5 - 07 October 2017, vol.28, pp.26
- X. **Investigation of the Effect of Cyclodextrin Nanoparticles on MCF 7 Breast Cancer Cell Line by Proteomics Approaches**  
BİLENSOY E., ÇELEBİER M., ERCAN A., NENNİ M., IŞIK G., ÖNCÜL S., ALTINÖZ S.  
7th BBBB International Conference on Pharmaceutical Sciences, 5 - 07 October 2017
- XI. **MCF-7 Breast Cell Proteome Analysis Determination With New UPLC/MS Method**  
KOÇAK E., ÖNCÜL S., NENNİ M., kaplan o., ÇELEBİER M., SÜSLÜ İ., ERCAN A., ALTINÖZ S.  
Symposium on Drug Research Development, 5 - 07 October 2017
- XII. **Screening for Cytotoxic Effects of Chlorokojoic Acid Derivatives**  
AYTEMİR M., Karakaya G., ERCAN A., ÖNCÜL S.  
Symposium on Drug Research And Development, 5 - 07 October 2017
- XIII. **Screening for Cytotoxic Effects of Chkorokojoic Acid Derivatives**  
AYTEMİR M., KARAKAYA G., ERCAN A., ÖNCÜL S.  
International Multidisciplinary Symposium on Drug Research Development (DRD2017), 5 - 07 October 2017

- XIV. **Cytotoxic Effect of Allomaltol Derivative on A375 Human Malignant Melanoma and MCF7 Breast Cancer Cells**  
ERCAN A., AYTEMİR M., KARAKAYA G., ÖNCÜL S.  
International Multidisciplinary Symposium on Drug Research Development (DRD2017), 5 - 07 October 2017
- XV. **Mild doses of doxorubicin alters apoptotic response and cell cycle arrest on both luminalA and triple negative breast cancer cell lines**  
ÖNCÜL S., ERCAN A.  
42nd FEBS Congress, Israel, 10 - 14 September 2017, vol.284, pp.286
- XVI. **Cell Death and Multidrug Resistance in Breast Cancer Cells: Are we Close to Cross the Threshold?**  
ERCAN A.  
2nd Global Insight Conference on Breast Cancer, Roma, Italy, 4 - 06 September 2017
- XVII. **CYTOTOXICITY OF A KOJIC ACID DERIVATIVE ON A375 HUMAN MALIGNANT MELANOMA AND HGF1 FIBROBLAST CELLS**  
AYTEMİR M., KARAKAYA G., ERCAN A., ÖNCÜL S.  
10th Joint Meeting On Medicinal Chemistry, Dubrovnik, Croatia, 25 - 28 June 2017
- XVIII. **Evaluation of Cholesterol-Targeted Amphiphilic Cyclodextrin Nanoparticles for Cancer Therapy**  
VARAN G., ÖNCÜL S., ERCAN A., BENİTO J., MELLET C. O., BİLENSOY E.  
Innovation in Medicine Meetings III Congress, 11 - 13 May 2017
- XIX. **Glukometre Cihazlarının Ulusal Verifikasyonu**  
TÜYLÜ KÜÇÜKKİLİNÇ Z. T., ERCAN A., TANIŞ F., UÇAR G.  
İnsülin Direnci Sempozyumu, Turkey, 22 - 23 March 2017
- XX. **Assessment of Low Dose Doxorubicin on Apoptosis and Multidrug Resistance in MCF 7 Cells**  
ERCAN A., ÖNCÜL S.  
6. MOKAD, Konya, Turkey, 27 - 30 October 2016
- XXI. **Doxorubicin induces multidrug resistance in MDA-MB-231 breast cancer cell line**  
Oncul S., ERCAN A.  
41st FEBS Congress on Molecular and Systems Biology for a Better Life, Kusadasi, Turkey, 3 - 08 September 2016, vol.283, pp.153
- XXII. **Demonstration of apoptosis via TUNEL assay and Codon 72 Polymorphism of p53 gene of MCF-7 and MDA-MB-231 cell lines upon treatment of Doxorubicin**  
Oncul S., ERCAN A.  
40th Congress of the Federation-of-European-Biochemical-Societies (FEBS) - The Biochemical Basis of Life, Berlin, Germany, 4 - 09 July 2015, vol.282, pp.270
- XXIII. **Investigation of the relationship between aromatase and seladin 1 in vivo and in vitro**  
KARAHAN H., LÜLE S., TÜYLÜ KÜÇÜKKİLİNÇ Z. T., ERCAN A., KELİCEN UĞUR E. P.  
SFN (Neuroscience 2014), 15 - 19 November 2014
- XXIV. **Investigation of p53 codon 72 polymorphism and cytotoxicity in HEPG2, MCF-7 and HEK293 cell lines**  
Oncul S., Aydın G., Ucar G., ERCAN A.  
38th Congress of the Federation-of-European-Biochemical-Societies (FEBS), Saint Peter, Guernsey And Alderney, 6 - 11 July 2013, vol.280, pp.85-86
- XXV. **Beta amyloid fibril destabilizing activities of some pyrazoline derivatives**  
ERCAN A., Yabanoglu S., Gokhan-Kelekci N., Salih B., Ucar G.  
35th Congress of the Federation-of-European-Biochemical-Societies, Gothenburg, Sweden, 26 June - 01 July 2010, vol.277, pp.80
- XXVI. **Beta amyloid fibril destabilizing activities of novel monoamine oxidase (MAO) inhibitors**  
Yabanoglu S., ERCAN A., Kelekci-Gokhan N., Salih B., Ucar G.  
34th Congress of the Federation-of-European-Biochemical-Societies, Prague, Czech Republic, 4 - 09 July 2009, vol.276, pp.352

## Supported Projects

KORKUSUZ F., DÖNMEZ G., ERCAN A., KARA Ö. S., Project Supported by Higher Education Institutions, KONSANTRİK VE İZOMETRİK İSKELET KASI KASILMASI ÖNCESİ VE SONRASINDA KAN İRİSİN, FNDC5 DÜZEYLERİNİN VE METABOLİK PROFİLİNİN İNCELENMESİ, 2019 - 2022

ERCAN A., Felekoğlu R., AYTEMİR M., Project Supported by Higher Education Institutions, Yeni Sentezlenen Antitirozinaz Aktiviteye Sahip Kojik Asit Türevlerinin A375 Malin Melanoma Hücre Hattında Sitotoksosite ve Hücre Ölümü Üzerine Etkisinin Aydınlatılması, 2019 - 2021

ERCAN A., ÖZTÜRK S. C., AYTEMİR M., ESENDAĞLI G., Project Supported by Higher Education Institutions, Klorokojik Asit Türevi Mannich Bazı Bileşiğinin UV ile İndüklenmiş Melanoma Karşı Koruyucu Etkisinin Değerlendirilmesi, 2019 - 2021  
ERKEKOĞLU Ü. P., ZEYBEK N. D., YILDIZTEKİN K. G., BALCI A., KÖSE Ö., SUR Ü., ERCAN A., YERSAL N., GÜMÜŞEL B., Project Supported by Higher Education Institutions, Endokrin Bozucu Kimyasal Maddelere Kombine Maruziyetin Toksik Etkilerinin Farklı Hücre Hatlarında Değerlendirilmesi: Endoplazmik Retikulum Stresi ve Oksidatif Stres, 2017 - 2020

AYTEMİR M., ERCAN A., Adak T., Project Supported by Higher Education Institutions, Kojik Asit Türevi Bileşiklerin Tasarımı, Sentezi ve Melanoma Hücrelerine Karşı Sitotoksisiteleri ile Tirozinaz İnhibisyonu Etkilerinin Değerlendirilmesi, 2018 - 2019

AYTEMİR M., ERCAN A., Project Supported by Higher Education Institutions, Klorokojik Asit Türevi Mannich Bazının A375 İnsan Malin Melanoma Hücreleri Üzerine Sitotoksik Etkilerinin Aydınlatılmasında Genomik Yaklaşımlar, 2018 - 2018

ERCAN A., ÖNCÜL S., Project Supported by Higher Education Institutions, Yeni Sentezlenen Bir Antrasiklin Türevinin Meme Kanseri Hücrelerinde p53 Apoptoz Yolağı ve Çoklu İlaç Direnci Üzerine Etkisi, 2016 - 2018

ERSU B., Olcay E. O., ERCAN A., Project Supported by Higher Education Institutions, Titanyum Alaşım Yüzeylerin selektif lazer ergitme işlemi ile kaplanması sonrası Saos2 proliferasyonunun değerlendirilmesi, 2016 - 2018

ERCAN A., Project Supported by Higher Education Institutions, Multidisipliner Kanser Araştırmaları, 2016 - 2017

UÇAR G., ERİKÇİ A., BAYSAL İ., ERCAN A., YÜKSEL TEK M., BİBEROĞLU K., TÜYLÜ KÜÇÜKKILINÇ Z. T., AYAZGÖK B., TACAL Ö., YABANOĞLU ÇİFTÇİ S., et al., Project Supported by Higher Education Institutions, ECF385 Biyokimya III Laboratuvar Ders İçeriğinin Klinik Biyokimya Yöntemleri ile Zenginleştirilerek Güncellenmesi, 2015 - 2016

AYTEMİR M., ERCAN A., Karakaya G., Project Supported by Higher Education Institutions, Allomaltol Türevi Yeni Mannich Bazlarının Sentezi ve Tirozinaz İnhibitörü Etkilerinin Değerlendirilmesi, 2015 - 2016

ERCAN A., Project Supported by Higher Education Institutions, KARACIĞER VE MEME KANSERİ HÜCRELERİNDE P53 YOLAĞINDAKİ GENLERİN MDR-1 GENİ İLE İLİŞKİSİNİN İNCELENMESİ, 2013 - 2015

## Metrics

Publication: 59

Citation (WoS): 399

Citation (Scopus): 560

H-Index (WoS): 8

H-Index (Scopus): 10

## Non Academic Experience

HACETTEPE ÜNİVERSİTESİ ECZACILIK FAKÜLTESİ

HACETTEPE ÜNİVERSİTESİ ECZACILIK FAKÜLTESİ

HACETTEPE ÜNİVERSİTESİ ECZACILIK FAKÜLTESİ

HACETTEPE ÜNİVERSİTESİ TIP FAKÜLTESİ